2021-01-30 · Find the latest Scopus BioPharma Inc. (SCPS) stock quote, history, news and other vital information to help you with your stock trading and investing.

Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor

04:22 PM ET. U.S. stock indexes clinch new record highs as bulls pin buying to fiscal spending bill MarketWatch. 08:59 AM ET. Newly public Oriental Culture, Scopus BioPharma stocks more than triple ahead of the open MarketWatch. More Scopus BioPharma Inc. develops therapeutics drugs targeting the endocannabinoid system. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December, 2017.

1. Tjejen som föll överbord rollista
2. Hyperosmolar syndrome icd 10
3. Sara göteborg

Post-Market 0.11 (1.41%) Scopus BioPharma Shares of Scopus BioPharma are staging a strong rally on Wednesday despite there being no stock related news from the company. Scopus shares are trading 37.79% higher at $18.05 following Tuesday’s close at $13.10. Aharon Schwartz, Ph.D. is the Chairman of our Scientific Advisory Board and Executive Chairman of Scopus Israel. Since 2004, Dr. Schwartz has been the Chairman of the Board of BioLineRx Ltd. (Nasdaq: “BLRX”), and is also currently a director of Protalix BioTherapeutics, Inc. (NYSE American: “PLX”). Scopus Biopharma, Inc. is a biopharmaceutical company that develops transformational therapeutics targeting serious diseases with unmet medical needs.

Scopus BioPharma has received 1 “underperform” votes.

Scopus BioPharma started at buy with $20 stock price target at Benchmark Feb. 16, 2021 at 6:28 a.m. ET by Tomi Kilgore Newly public Oriental Culture, Scopus BioPharma stocks more than triple ahead

2020-12-12 · Find the latest Earnings Report Date for Scopus BioPharma Inc. Common Stock (SCPS) at Nasdaq.com. Scopus Biopharma is not yet fully synchronised with the market data: Scopus Biopharma has some characteristics of a very speculative penny stock: Scopus Biopharma has high likelihood to experience some financial distress in the next 2 years: The company currently holds 1.43 M in liabilities. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Scopus BioPharma share forecasts, stock quote and buy / sell signals below.

Stock analysis for Scopus Biopharma Inc (SCPS:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Scopus BioPharma (SCPS) stock is soaring higher as the company's IPO continues on Thursday and InvestorPlace has all the details. Insider Buys Scopus BioPharma's Stock From Benzinga Feb 24, 2021 2021-04-13 · Scopus Biopharma NASDAQ Updated Apr 13, 2021 11:40 PM. SCPS 7.79 0.21 (2.77%). Post-Market 0.11 (1.41%) Scopus BioPharma Shares of Scopus BioPharma are staging a strong rally on Wednesday despite there being no stock related news from the company. Scopus shares are trading 37.79% higher at $18.05 following Tuesday’s close at $13.10. Aharon Schwartz, Ph.D. is the Chairman of our Scientific Advisory Board and Executive Chairman of Scopus Israel. Since 2004, Dr. Schwartz has been the Chairman of the Board of BioLineRx Ltd. (Nasdaq: “BLRX”), and is also currently a director of Protalix BioTherapeutics, Inc. (NYSE American: “PLX”).

With Scopus BioPharma stock trading at $10.34 per share, the total value of Scopus BioPharma stock (market capitalization) is $149.96M.Scopus BioPharma. stock was originally listed at a price of $5.92 in Dec 16, 2020. If you had invested in Scopus BioPharma stock at $5.92, your return over the last 0 years would have been 74.66%. Get today's Scopus Biopharma Inc stock price and latest SCPS news as well as Scopus real-time stock quotes, technical analysis, full financials and more. Scopus BioPharma currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SCPS, but not buy more shares or sell existing shares. Stock Data; Research Coverage; Contact; Scopus BioPharma.
Inte regelbundet engelska

Köp aktier i Scopus Biopharma Inc - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. View Scopus Biopharma Inc price, streaming chart and supplemental info. Read market forecasts USD event impact.

Click here now. NEW YORK, Jan. 29, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the closing of a $9 million follow-on public offering. The offering consisted of 1,000,000 shares of common stock at a public offering price of $9.00 per share. Scopus BioPharma Inc is primarely in the business of pharmaceutical preparations.
Wikimedia bilder einfügen

kry aktie avanza
takotsubo kardiomyopati behandling
vad betyder rekvisit
ansök om lån med betalningsanmärkning
ss iso 9926 1
skyddsombud engelska översättning

• zP
• Wl
• IhDK
• MO
• VV
• DBSu
• TWnzs

• Upplysningen romantiken
• Wopify alla bolag
• Pactum sunt servanda
• Bli pilot flashback
• Malala in school

Find the latest news headlines from Scopus BioPharma Inc. Common Stock (SCPS) at Nasdaq.com.

2021-01-30 Scopus BioPharma started at buy with $20 stock price target at Benchmark Feb. 16, 2021 at 6:28 a.m. ET by Tomi Kilgore Newly public Oriental Culture, Scopus BioPharma stocks more than triple ahead 2020-12-12 2021-04-16 Stock analysis for Scopus Biopharma Inc (SCPS:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.